Difference between revisions of "Cytarabine liposomal (DepoCyt)"
Line 1: | Line 1: | ||
==General information== | ==General information== | ||
− | Class/mechanism: | + | Class/mechanism: Pyrimidine analog, mimics cytosine. Converted intracellularly into cytarabine-5-triphosphate (ara-CTP). Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf Cytarabine liposomal (DepoCyt) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/cytarabineliposomal.pdf Cytarabine liposomal (DepoCyt) package insert (locally hosted backup)]</ref> |
− | |||
− | Pyrimidine analog, mimics cytosine. Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase. | ||
− | |||
− | |||
− | |||
− | <ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf Cytarabine liposomal (DepoCyt) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/cytarabineliposomal.pdf Cytarabine liposomal (DepoCyt) package insert (locally hosted backup)]</ref> | ||
<br>Route: IT | <br>Route: IT | ||
− | <br>Extravasation: | + | <br>Extravasation: n/a |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. |
Revision as of 22:28, 9 December 2011
General information
Class/mechanism: Pyrimidine analog, mimics cytosine. Converted intracellularly into cytarabine-5-triphosphate (ara-CTP). Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.[1][2]
Route: IT
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Cytarabine liposomal (DepoCyt) patient drug information (Chemocare)[3]
- Cytarabine liposomal (DepoCyt) patient drug information (UpToDate)[4]
Regimens
Standard format will be:
<acronym (if any)> <generic drug1, generic drug2, generic drug3, etc.> (disease)